<DOC>
	<DOCNO>NCT01970748</DOCNO>
	<brief_summary>Randomized comparison within endoscopic esophageal varix ligation versus non-selective beta-blocker primary prevention esophageal variceal bleed patient HCC .</brief_summary>
	<brief_title>Primary Prevention Patients With Hepatocellular Carcinoma Concomitant Esophageal Varices</brief_title>
	<detailed_description>Gastroesophageal variceal bleed major complication cirrhosis high rate rebleeding mortality . In 20 30 year , medical advance significantly improve prognosis variceal bleeding . Nevertheless , mortality gastroesophageal variceal bleeding still nearly 20 30 % . Hepatocellular carcinoma ( HCC ) one common malignancy Asian , also special group portal hypertension . Studies Italy , 50 % patient diagnose HCC concomitant esophageal varix . HCC portal thrombosis cause HCC independent risk factor gastroesophageal bleed . Once bleeding , rebleeding rate 50 % even early use vasoconstrictor agent endoscopic therapy , generally 2 time patient cirrhosis . According 2010 Baveno V recommendation , non-selective beta-blockers ( NSBB ) endoscopic variceal ligation ( EVL ) first choice primary prevention first variceal bleed cirrhotic patient . However , risk factor variceal bleed cause HCC cirrhosis different , portal hypertension particularly high patient HCC may combine portal vein thrombosis . NSBB sufficient decrease portal hypertension prevent variceal bleed clear . In Hepatology 2010 , Lebrec claim NSBB use cirrhotic patient refractory ascites poor prognosis , main cause death progression HCC sepsis , although impact NSBB HCC patient entirely clear , issue remind clinician careful use NSBB patient . Since NSBB possible adverse effect , use EVL prevent bleed patent HCC superior NSBB ? These need study clarify . So designed study evaluate feasibility effectiveness use EVL NSBB prevent first bleed patient HCC concomitant esophageal varix .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Between 20 80 year old Hepatocellular carcinoma ( HCC ) associate esophageal varix F2 F3 esophageal varix ( Beppu et al classification ) Hepatocellular carcinoma ( HCC ) associate portal thrombosis History esophageal variceal bleeding Had receive endoscopic variceal ligation ( EVL ) endoscopic injection sclerotherapy ( EIS ) Pregnancy , patient terminal illness ( terminal cancer , heart failure , renal failure ... ) Propranolol contraindication ( atrioventricular block , heart failure , chronic obstructive pulmonary disease , asthma , poorly control diabetes , severe peripheral arterial disease ... )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Variceal bleeding</keyword>
	<keyword>Portal hypertension</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Endoscopic variceal ligation</keyword>
	<keyword>Non-selective beta-blocker</keyword>
</DOC>